Transgene and BioInvent International AB will jointly present a poster on translational data and updated clinical results from the Phase I study of BT-001 at the upcoming European Society for Medical Oncology (ESMO) Annual Meeting. ESMO will take place in Berlin, Germany, from October 17 to 21, 2025. Key findings of the abstract include: Intra-tumoral (IT) BT-001 injection in combination with intravenous (IV) pembrolizumab was well tolerated with a manageable safety profile.
The data show encouraging and sustained anti-tumor activity in patients with advanced refractocry tumors. One patient with PD(L)-1 resistant melanoma and one patient with heavily pretreated and Immune Checkpoint Inhibitor (ICI)-naive leiomyosarcoma showed partial response (iPR) lasting 6 and 16 months respectively, among the 13 patients who received the combination of IT BT-001 (at 107 pfu/mL and 108 pfu/mL) and IV pembrolizumab. Tumor shrinkage was observed in both injected and non-injected lesions.
BT-001 could be an effective option to improve the response to ICI in refractory patients.
